Abstract
Studies were undertaken to determine the therapeutic effects of liposome-encapsulated 1-β-d-arabinofuranosylcytosine (lip-ara-C) against intracranial L1210 leukemia. The effects of administration route, drug dosage, liposome type, and tumor load on therapeutic efficacy were also studied. One hundred % mice were cured after a single intracranial 40 mg/kg dose of lip-ara-C, dependent on tumor load. Intracranial lip-ara-C was more effective than i.v. lip-ara-C. A single i.v. dose of lip-ara-C was therapeutically superior to 5-day i.v. infusion of the free drug. Intracranial or i.v. lip-ara-C at therapeutic doses resulted in less systemic toxicity than i.v. infusion of free ara-C, suggesting possible use of lip-ara-C as an adjunct to treatment of central nervous system leukemia.
Footnotes
-
↵1 This work was partially supported by a grant from the Association for Research on Childhood Cancer.
-
↵3 To whom requests for reprints should be addressed.
-
↵4 A unit of the New York State Department of Health
- Received February 3, 1989.
- Revision received May 15, 1989.
- Accepted May 26, 1989.
- ©1989 American Association for Cancer Research.
Volume 49, Issue 18
